Welcome to our dedicated page for eXoZymes news (Ticker: EXOZ), a resource for investors and traders seeking the latest updates and insights on eXoZymes stock.
eXoZymes Inc. (NASDAQ: EXOZ) is a biotechnology company that publicly reports on developments in its AI-enhanced, cell-free biomanufacturing platform. The company focuses on exozymes, which it defines as advanced enzymes engineered to operate in bioreactors without living cells, transforming sustainable feedstock into essential chemicals, nutraceuticals, medicines, biofuels, and other valuable biochemicals.
The EXOZ news feed highlights updates that the company shares through press releases and investor communications. These include technical milestones such as the reported 100-fold scale-up of N-trans-caffeoyltyramine (NCT) production with over 99% conversion from feedstock to product using its exozyme-based process, as well as earlier progress going from concept to gram-scale NCT production with high yield and purity. News items also cover the evolution of its programs around NCT, santalene, and other highly valuable natural product molecules.
Investors and followers of eXoZymes can use the news page to review announcements about quarterly update webinars, investor conference presentations, and participation in industry initiatives. The company has issued news about being selected as a core industry partner in an NSF-funded initiative for modular cell-free biomanufacturing, and about leadership roles in BioMADE governance committees related to cell-free enzyme pathways and bioindustrial manufacturing.
In addition, the EXOZ news stream includes items on management appointments and commentary from company leaders on topics such as AI in life sciences, synthetic biology scaling challenges, and the concept of exozymes as next generation biomanufacturing. By following this page, readers can see how eXoZymes presents its scientific progress, platform maturation, and communication with the investment community over time.
eXoZymes (NASDAQ:EXOZ) provided a fiscal 2025 update on March 31, 2026, reporting increased operating investment, platform validation, and financing preparations.
Key figures: Operating expenses $9.72M, Net loss $9.16M, and Cash $3.04M as of December 31, 2025. The company advanced pilot-scale cell-free biomanufacturing and filed an S-3 in January 2026 ahead of an imminent financing round.
eXoZymes (NASDAQ:EXOZ) will host a webinar on Tuesday, March 31, 2026 at 5:30 PM ET to review fourth quarter and full year 2025 results. CEO Michael Heltzen and select management will discuss recent developments, ongoing initiatives, anticipated milestones, and hold a Q&A.
A press release with results will be issued prior to the call. Investors can pre-register and access the live webinar via the company’s investor relations site at https://exozymes.com/investor.
eXoZymes (NASDAQ:EXOZ) reported a successful pilot-scale validation with Cayman Chemical, advancing its cell-free biomanufacturing from 1L to a 100-liter run in under one year. The partner produced over 500 grams of pharma-grade N-trans-caffeoyltyramine (NCT) at 99.6% purity with ~99% conversion.
This external, independent run demonstrated scalability, robustness under real-world conditions (pH variation, precipitation), and material available for formulation, validation, and commercialization discussions.
eXoZymes (NASDAQ:EXOZ) announced that CCO Damien Perriman will present a solution for scaling production of NCT at the MISTA Symposium Healthspan on March 18, 2026 in San Francisco. The talk will cover NCT's role in metabolic health and cell-free enzyme production using the company's AI-designed exozyme platform.
The company says its cell-free enzyme cascades aim to enable scalable supply of a rare plant-derived molecule for nutraceutical and pharmaceutical applications.
eXoZymes (NASDAQ:EXOZ) unveiled a refreshed brand identity and redesigned website on February 10, 2026, aligning external presentation with a refined strategic focus on pharmaceutical and high-value nutraceutical markets.
The company said it will prioritize its AI-designed, cell-free enzyme cascade platform to target regulated, high-margin applications and pursue platform leverage, partnerships, and IP development.
eXoZymes (NASDAQ:EXOZ) reported results from a 100-liter pilot run producing N-trans-caffeoyltyramine (NCT): ~99% reaction conversion, 91% process recovery, 90% isolated yield, 535 grams isolated, and 99.6% pharma-grade purity. The run was executed by Cayman Chemical, demonstrating protocol transferability and improved reaction performance at larger scale. eXoZymes plans 2026 work to establish commercial supply chains, expand volumes, form strategic partnerships, and finalize technology-transfer packages for commercial manufacturing and formulation development.
eXoZymes (NASDAQ:EXOZ) reported a successful 100× scale-up of its N-trans-caffeoyltyramine (NCT) production using its cell-free, exozyme-based biomanufacturing platform on December 11, 2025. The scaled run delivered >99% conversion from feedstock to product and was executed under partner-operated conditions by Cayman Chemical, demonstrating process transferability and robustness. eXoZymes said downstream isolation and full data analysis are ongoing, with additional technical details expected in early 2026.
eXoZymes (NASDAQ:EXOZ) will host a Q3 2025 operational update webinar at 5:00 PM ET on November 13, 2025 covering results through the quarter ended October 31, 2025. Management will review commercialization progress, recent hires, and near-term milestones.
Q3 highlights: net loss of $2.29 million (quarter), year-to-date loss of $6.5 million, operating expenses up $0.9 million versus prior year, and $5.1 million cash on hand, described as supporting operations into early Q2 2026. Company named Amy Lunzer chief of staff and promoted co-founder Tyler Korman, PhD to chief scientific officer. A recording and live webcast will be available on investor relations.
eXoZymes (NASDAQ:EXOZ) announced leadership changes effective November 13, 2025: co-founder Tyler Korman, PhD, is appointed Chief Scientific Officer and Amy Lunzer is named Chief of Staff. Korman will lead scientific strategy after roles from Director of R&D to VP of Research and says the company aims to scale AI-enhanced enzyme biomanufacturing for nutraceuticals and pharmaceuticals. Lunzer brings business, supply-chain, and operations experience. Management changes take effect immediately and will be discussed on the company’s 2025 Q3 update call at 5:00 PM ET.
eXoZymes (NASDAQ:EXOZ) will host a Third Quarter 2025 update webinar on Thursday, November 13, 2025 at 5:00 PM ET.
CEO Michael Heltzen and select management will review Q3 2025 developments, ongoing initiatives, anticipated milestones, and hold a Q&A for investors. Investors can pre-register and access the live webinar via the company’s investor relations website at https://exozymes.com/investor#webinar.